Managing a Patient Who Refuses Lantus (Insulin Glargine)
When a patient refuses Lantus, you must explore alternative basal insulin options or consider GLP-1 receptor agonists as first-line injectable therapy, while addressing the underlying reasons for refusal through patient education and shared decision-making. 1
Immediate Assessment and Alternative Strategies
1. Identify the Reason for Refusal
Before switching medications, determine why the patient refuses Lantus:
- Fear of injections: Consider oral agents first if clinically appropriate, or discuss once-weekly GLP-1 RAs
- Cost concerns: Biosimilar insulin glargine products may be more affordable
- Injection site pain: This is a known adverse effect of insulin glargine 2
- Misconceptions about insulin: Address beliefs about insulin causing complications or representing "failure"
- Complexity concerns: Simplify the regimen
2. Clinical Context Determines Next Steps
If the patient has Type 2 diabetes and is not severely hyperglycemic:
- Consider GLP-1 receptor agonists FIRST before any insulin, especially if the patient has cardiovascular disease or needs weight loss 1
- GLP-1 RAs provide 1-2% A1C reduction when added to metformin and have cardiovascular benefits 1
- This approach aligns with 2025 ADA guidelines prioritizing GLP-1 RAs over basal insulin in many scenarios
If A1C ≥10% (86 mmol/mol) or blood glucose ≥300 mg/dL with symptoms:
- Insulin remains necessary 1, 3
- You cannot delay insulin therapy in this situation—the patient needs immediate glycemic control
3. Alternative Basal Insulin Options
If the patient needs basal insulin but refuses Lantus specifically:
Alternative long-acting basal insulins:
- Insulin detemir (given once or twice daily) 4
- Insulin degludec (ultra-long acting, >42 hours duration) 3
- NPH insulin (intermediate-acting, requires twice-daily dosing) 1, 4
Key differences:
- NPH is less expensive but has a peak action (6-8 hours), increasing nocturnal hypoglycemia risk compared to glargine 5, 6
- Detemir may require twice-daily dosing but has similar hypoglycemia rates to glargine 4
- Degludec offers even longer duration than glargine with potentially less hypoglycemia 3
4. Dosing Strategy for Alternative Basal Insulin
If switching from planned Lantus to NPH:
- Use 80% of the calculated Lantus dose, divided into two daily injections 1
- Example: If Lantus dose would be 20 units once daily, give NPH 8 units twice daily (morning and evening)
If switching to detemir:
- Start at equivalent dose to Lantus, but may need twice-daily dosing 4
- Give once daily initially; if glucose control inadequate, split into twice-daily dosing
Initial dosing for insulin-naive patients (applies to any basal insulin):
- 0.2-0.3 units/kg for patients ≥70 years or GFR <60 mL/min 4
- 0.4 units/kg for blood glucose 140-200 mg/dL 4
- 0.5 units/kg for blood glucose 201-400 mg/dL 4
Critical Warnings and Pitfalls
Do NOT Use Sliding Scale Insulin Alone
Avoid the common error of abandoning basal insulin entirely and using only correction-dose (sliding scale) insulin 4. This approach:
- Increases risk of hyperglycemia 3-fold 4
- Results in poor glycemic control
- Is specifically discouraged by Endocrine Society guidelines 4
Basal-Bolus Regimen Requirements
If the patient requires scheduled insulin therapy:
- 50% of total daily dose should be basal insulin (whether Lantus, NPH, or alternative) 4
- 50% should be nutritional/prandial insulin (rapid-acting before meals) 4
- Correction insulin is added on top of scheduled doses 4
Mixing Prohibition
Critical FDA warning: Do NOT dilute or mix Lantus with any other insulin or solution 2. This causes:
- Loss of blood glucose control
- Unpredictable insulin action
- Potential serious adverse outcomes
This prohibition applies specifically to insulin glargine due to its unique pH-dependent precipitation mechanism.
Patient Education Approach
Address Common Concerns
"Insulin means my diabetes is worse":
- Explain that diabetes is progressive; insulin is a tool, not a punishment
- Type 2 diabetes naturally progresses due to declining beta-cell function 7
"I'm afraid of low blood sugar":
- Modern basal insulins like glargine have lower nocturnal hypoglycemia rates than older insulins (NPH) 6, 8
- Proper titration and glucose monitoring minimize this risk 7
"Injections are painful":
- Injection site pain occurs but is typically mild 6
- Rotating injection sites (upper arm, abdomen, thigh) reduces discomfort 2
- Ultra-fine needles minimize pain
Shared Decision-Making
Present options clearly:
- GLP-1 RA (if appropriate clinically): Once-weekly injection, weight loss, CV benefits
- Alternative basal insulin: Similar efficacy to Lantus with different dosing schedules
- Intensified oral therapy: Only if not severely hyperglycemic and willing to accept slower A1C improvement
Monitoring and Titration
Regardless of which insulin is chosen:
- Test fasting blood glucose daily during titration 7
- Target fasting glucose <100 mg/dL (5.5 mmol/L) to achieve A1C <7% 7
- Titrate dose every 3 days based on fasting glucose readings 7
- Increase by 2 units if no hypoglycemia and glucose above target 7
When Insulin Cannot Be Avoided
In hospitalized patients or those with severe hyperglycemia, insulin is non-negotiable 4. In these situations:
- Explain that temporary insulin use may allow transition to other agents once stabilized
- Use scheduled basal-bolus regimen, not sliding scale alone 4
- Discontinue oral agents temporarily in hospitalized patients 4
The key is never to accept therapeutic inertia—if the patient refuses one option, immediately pivot to an evidence-based alternative rather than accepting poor glycemic control.